<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00757562</url>
  </required_header>
  <id_info>
    <org_study_id>P02994</org_study_id>
    <nct_id>NCT00757562</nct_id>
  </id_info>
  <brief_title>Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)</brief_title>
  <official_title>Multiple-Dose Safety and Tolerance Study of Desloratadine in Atopic Pediatric Subjects and Pediatric Subjects With Chronic Idiopathic Urticaria, Ages &gt;=2 to &lt;12 Years, Who Are Poor Metabolizers of Desloratadine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to evaluate the safety and tolerance of desloratadine after 5 weeks
      of repetitive dosing in children ages 2 to 12 years old with allergic hypersensitivity or
      chronic hives. All of the subjects enrolled in this trial were previously identified in an
      earlier trial to be poor metabolizers of desloratadine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2002</start_date>
  <completion_date type="Actual">October 1, 2003</completion_date>
  <primary_completion_date type="Actual">October 1, 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerance</measure>
    <time_frame>Weekly throughout the 5-week study (Day 1, Day 8, Day 15, Day 22, Day 29, and Day 36).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration data (of desloratadine to loratadine) prior to administration of desloratadine on Days 15 and Days 36.</measure>
    <time_frame>Days 15 and Days 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Chronic Idiopathic Urticaria</condition>
  <condition>Atopy</condition>
  <arm_group>
    <arm_group_label>DL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desloratadine syrup once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo syrup once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desloratadine</intervention_name>
    <description>desloratadine syrup: 1.25 mg (2.5 mL) for subjects &gt;=2 to &lt;6 years, 2.5 mg (5 mL) for subjects &gt;=6 to &lt;12 years, orally once daily in the morning for 36 days.</description>
    <arm_group_label>DL</arm_group_label>
    <other_name>SCH 034117</other_name>
    <other_name>Clarinex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo syrup: 2.5 mL for subjects &gt;=2 to &lt;6 years, 5 mL for subjects &gt;=6 to &lt;12 years, orally once daily in the morning for 36 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must:

          -  have been previously identified through the previous study P03031 to be atopic or with
             chronic idiopathic urticaria and be a poor metabolizer of desloratadine.

          -  have clinical laboratory tests within normal limits.

          -  be in good health, free of any clinically significant disease that could interfere
             with the study.

          -  normal 12-lead ECG

        Exclusion Criteria:

        Subjects who:

          -  have a history of any clinically significant local or systemic infectious disease
             within 4 weeks prior to treatment.

          -  have taken any medication that is restricted by the protocol or failed to satisfy
             washout requirements.

          -  are allergic to desloratadine.

          -  have used a loratadine- or desloratadine-containing product within the past 30 days.

          -  are female and menstruating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2008</study_first_submitted>
  <study_first_submitted_qc>September 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2008</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

